Malaria Vaccine Market

Malaria Vaccine Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Vaccine Type (Pre-Erythrocytic, Erythrocytic, Multi-antigen, Others), By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others), Region and Competition

Global Malaria Vaccine Market will witness an impressive growth during the forecast period, 2024-2028. This can be ascribed to the increasing prevalence of malaria, growing R&D activities and increasing investment in healthcare infrastructure. Malaria is a major public health problem in many developing countries, particularly in sub-Saharan Africa. The high burden of the disease has created a strong demand for effective malaria vaccines. This has led to significant investment in the development of vaccines that can prevent malaria infection or reduce its severity. In 2021, there were 247 million cases of malaria, up from 245 million cases in 2020, according to the most recent World Malaria Report. Compared to 625,000 in 2020, the expected number of malaria-related deaths was 619, 000 in 2021.

Advancements in biotechnology have significantly accelerated the development of malaria vaccines. In recent years, there has been a greater understanding of the molecular and cellular mechanisms involved in malaria infection, which has led to the identification of potential vaccine candidates. Additionally, advances in vaccine development technologies, such as DNA vaccines and viral vector-based vaccines, have allowed for the creation of more effective and safer malaria vaccines, thereby opening new prospects for the growth of global malaria vaccine market in the next few years.

The growth of the malaria vaccine market faces several challenges, including scientific complexities due to the complex nature of the malaria parasite and its ability to mutate rapidly, financial constraints in terms of research and development costs, regulatory hurdles for approval and distribution, limited infrastructure in some regions for effective vaccine distribution, and the growing trend of vaccine hesitancy and political instability in malaria-endemic areas. Developing a vaccine requires approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This process can be lengthy and expensive, and the requirements for approval can be stringent, making it difficult for smaller companies to navigate the process.

Increasing Prevalence of Malaria

The growing prevalence of malaria is one of the key drivers of the global malaria vaccine market. Malaria is a life-threatening disease that is caused by the Plasmodium parasite, which is transmitted to humans through the bite of infected mosquitoes. Nearly half of the world's population was predicted to be in danger of malaria in 2021 by WHO. 619 000 deaths from malaria were anticipated in 2021. A disproportionately large amount of the worldwide malaria burden is placed on the WHO African Region. 95% of malaria cases and 96% of malaria deaths occurred in the Region in 2021. In the region, 80% of all malaria deaths were in children under the age of five. The high prevalence of malaria has led to increased investment in the development of new treatments and preventive measures, including vaccines. Malaria vaccines have the potential to be an important tool in the fight against the disease, particularly in high-burden areas where other interventions may be less effective. The growing prevalence of malaria has also led to increased investment in research and development by pharmaceutical companies and non-profit organizations. This has led to the development of new vaccine candidates and the testing of existing vaccines in new populations.

Increasing Research & Development

Increasing research and development (R&D) activities are a key driver of the growth of the global malaria vaccine market. The development of effective malaria vaccines is critical to reducing the burden of this deadly disease, particularly in low- and middle-income countries where malaria is most prevalent. The high incidence of malaria in sub-Saharan Africa and other parts of the world has led to increased investment in the development of new vaccines. Many pharmaceutical companies, academic institutions, and non-profit organizations are working on developing new malaria vaccines and improving existing ones. R&D activities in the global malaria vaccine market are focused on several areas, including the identification of new vaccine targets, the development of novel vaccine delivery systems, and the testing of new vaccine candidates in clinical trials. Increasing R&D activities in the global malaria vaccine market have been supported by government funding, private investment, and philanthropic donations. For instance, the Bill and Melinda Gates Foundation has provided significant funding for malaria vaccine research and development, including support for the development of the Mosquirix vaccine.

Increasing Investments

Increasing investment in developing and improvising healthcare infrastructure is another important driver of the growth of the global malaria vaccine market. The development of effective malaria vaccines is only one part of the solution to combating this disease. Equally important is the establishment of a strong healthcare infrastructure that can effectively deliver vaccines to those who need them. In many low- and middle-income countries where malaria is most prevalent, healthcare infrastructure is often inadequate or nonexistent, making it difficult to effectively deliver vaccines and other essential healthcare services. Increasing investment in healthcare infrastructure can help to address this problem by improving the availability and accessibility of healthcare services, including vaccines. This includes investment in healthcare facilities, medical equipment, healthcare personnel, and healthcare logistics. For instance, investment in the construction of new healthcare facilities, such as clinics and hospitals, can help to expand access to healthcare services in underserved areas. Investment in medical equipment, such as refrigerators and freezers, can help to ensure that vaccines are stored properly and remain effective. Increased investment in healthcare infrastructure has been supported by both government and private sector funding. Increasing investment in healthcare infrastructure is driving the growth of the global malaria vaccine market by improving the availability and accessibility of healthcare services, including vaccines.

Recent Developments

The malaria vaccine, known as R21/Matrix-M, which is manufactured by the Serum Institute of India, has received clearance from the Ghanaian government to be used in the country. This marks a significant step forward in the fight against malaria, which is a major public health problem in Ghana and other sub-Saharan African countries.

Mosquirix is a vaccine that is designed to provide protection against Plasmodium falciparum, the deadliest species of malaria parasite. The vaccine was developed by GlaxoSmithKline (GSK) in partnership with the PATH Malaria Vaccine Initiative, and it has been approved for use by the European Medicines Agency (EMA).

CVac is a whole-parasite malaria vaccine that uses genetically modified parasites to stimulate an immune response. In 2021, Novartis announced that it had completed a Phase 1 clinical trial of the CVac vaccine, which showed that the vaccine was safe and well-tolerated in healthy volunteers. The company plans to move forward with Phase 2 clinical trials to evaluate the efficacy of the vaccine.

In 2021, Serum Institute of India announced that it had partnered with the University of Oxford to develop a new mRNA-based malaria vaccine. The vaccine will use the same technology that was used to develop the Pfizer-BioNTech and Moderna COVID-19 vaccines. The mRNA vaccine has the potential to provide a more effective immune response compared to traditional vaccines.

Market Segmentation

Global Malaria Vaccine Market can be segmented by vaccine type, by route of administration, and by region. Based on vaccine type, global malaria vaccine market can be divided into Pre-Erythrocytic, Erythrocytic, Multi-antigen, and Others. Based on route of administration, the global malaria vaccine market is divided into Intramuscular, Subcutaneous, Intradermal, and Others. Regionally, the Malaria Vaccine Market can be categorized into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

Market Players

GlaxoSmithKline, Plc., Novartis AG, Takeda Pharmaceutical Company, Sanaria Inc., Merck & Co., Johnson & Johnson, Pfizer Inc., Serum Institute of India Private Limited, Bharat Biotech International Limited, Moderna Inc are some of the leading players operating in the Global Malaria Vaccine Market.

Report Scope:

In this report, Global Malaria Vaccine Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

• Global Malaria Vaccine Market, By Vaccine Type:
• Pre-Erythrocytic
• Erythrocytic
• Multi-antigen
• Others
• Global Malaria Vaccine Market, By Route of Administration:
• Intramuscular
• Subcutaneous
• Intradermal
• Others
• Global Malaria Vaccine Market, By Region:
• North America
• United States
• Canada
• Mexico
• Europe
• Germany
• United Kingdom
• France
• Italy
• Spain
• Asia Pacific
• India
• Japan
• South Korea
• Australia
• Vietnam
• Indonesia
• Myanmar
• South America
• Brazil
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Egypt
• Turkey
• Nigeria

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Malaria Vaccine Market.

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order. Single User license will be delivered in PDF format without printing rights